title: Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH-cortisol and renin-angiotensin-aldosterone.
abstract: The chemotherapies of FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) and FOLFIRI (folinic acid + 5-fluorouracil + irinotecan) are effective for a variety of malignant tumors. In particular, the sequential chemotherapy of FOLFOX/FOLFIRI has become the preferred post-operational treatment approach for gastrointestinal cancer and an important palliative care program for advanced cancer. However, the sequential chemotherapy of FOLFOX/FOLFIRI showed severe side effects due to the fact that the toxicity of the drugs can be enhanced by each other. Here, we report the dynamic changes in the activities of serum ACTH, cortisol, renin, angiotensin, and aldosterone in patients following multiple cycles of FOLFOX/FOLFIRI sequential chemotherapy. We found that the sequential chemotherapy might cause damage to the activities of the endocrine cells and/or the sympathetic nerve, and alter endocrine function, specifically the ACTH-cortisol and renin-angiotensin-aldosterone axes.
authors.affiliation: The Affiliated Hospital of Medical College, Hangzhou Normal University, 126 Wenzhou Road, Hangzhou, 310015, Zhejiang Province, China. hcx588@hotmail.com
authors.forename: Changxin
authors.initials: C
authors.lastname: Huang
authors.forename: Yiqian
authors.initials: Y
authors.lastname: Jiang
authors.forename: Guangliang
authors.initials: G
authors.lastname: Duan
authors.forename: Zhaoyang
authors.initials: Z
authors.lastname: Li
authors.forename: Lingzhi
authors.initials: L
authors.lastname: Chen
authors.forename: Xuechun
authors.initials: X
authors.lastname: Wang
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000368:Aged; D000450:Aldosterone / Q000097:blood; D000809:Angiotensins / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016022:Case-Control Studies; D005472:Fluorouracil / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011379:Prognosis; D012083:Renin / Q000097:blood
chemical_list: D000809:Angiotensins; D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D000450:Aldosterone; D000324:Adrenocorticotropic Hormone; D012083:Renin; D002955:Leucovorin; D005472:Fluorouracil; D006854:Hydrocortisone; D002166:Camptothecin